Oncocross Co., Ltd. develops drugs for the treatment of cancers, rare diseases, and intractable diseases in South Korea. Its products pipeline includes OC101 for liver cirrhosis; OC101+OC111 for non-alcoholic steatohepatitis; OC201+OC202e for Inhibition of cancer metastasis; OC211, a Pan-KRAS Inhibitor; OC221, an immuno-oncology combination; OC514 to treat amyotrophic lateral sclerosis and Duchenne muscular dystrophy; and OC701 to treat atopic dermatitis. The company is also developing OJP3101 for metabolic disease; OJP3101 for Cardiovascular Disease; ODP9401 for metabolic disease; and ODP2201, ODP2301, and ODP2401 to treat oncology-related diseases. It has a collaboration agreement with various pharmaceutical companies, research institutes, and bio-techs. The company was founded in 2015 and is based in Seoul, South Korea.
Metrics to compare | 382150 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship382150PeersSector | |
|---|---|---|---|---|
P/E Ratio | −10.2x | −9.4x | −0.5x | |
PEG Ratio | 0.42 | −0.11 | 0.00 | |
Price/Book | 5.3x | 3.3x | 2.6x | |
Price / LTM Sales | 96.2x | 10.9x | 3.2x | |
Upside (Analyst Target) | - | 40.4% | 51.4% | |
Fair Value Upside | Unlock | 14.9% | 8.5% | Unlock |